Retatrutide UK | Research Peptide

Retatrutide (LY3437943) is a synthetic triple incretin receptor agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. It is one of the most extensively studied investigational peptides in metabolic research, with Phase 3 clinical trial data published in May 2026. Precision Chain Peptides supplies Retatrutide 20mg as a lyophilised vial, ≥99% purity, HPLC-verified, and UK-dispatched for scientific research use.

What is Retatrutide?

Retatrutide is a synthetic peptide analogue developed by Eli Lilly and Company (LY3437943). Unlike dual agonists such as tirzepatide (GLP-1/GIP), Retatrutide adds glucagon receptor agonism to create a distinct triple-receptor metabolic profile. This combination has generated significant scientific interest for its effects on energy homeostasis, adipose tissue biology, and insulin sensitivity.

TRIUMPH-1 Phase 3 Trial Results

On 21 May 2026, Eli Lilly published topline results from the TRIUMPH-1 Phase 3 randomised controlled trial — the largest controlled study of Retatrutide to date. Key findings at 80 weeks in the highest-dose group:

Mean body weight reduction of 28.3%
45.3% of participants achieved ≥30% weight reduction — a threshold previously associated only with bariatric surgery
Significant improvements in blood pressure, lipid profiles, and glycaemic indices
Favourable tolerability profile consistent with the GLP-1 receptor agonist class

These results build on the Phase 2 RCT published in The New England Journal of Medicine (2023), which reported approximately 24% mean body weight reduction at 48 weeks in the 12mg dose group.

Mechanisms of Action

GLP-1 Receptor Agonism

Promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central nervous system pathways.

GIP Receptor Agonism

Enhances insulin secretion and influences adipose tissue metabolism and energy storage.

Glucagon Receptor Agonism

Stimulates hepatic glucose production and increases energy expenditure, potentially enhancing fat oxidation and thermogenesis — the key differentiator from dual agonists.

Areas of Scientific Interest

Triple incretin receptor agonism and comparative pharmacology
Metabolic rate and energy expenditure research
Adipose tissue biology and lipid metabolism
Insulin sensitivity and glucose homeostasis models
Cardiovascular risk factor modulation
Obesity biology and body weight regulation mechanisms

Retatrutide vs Tirzepatide vs Semaglutide

Retatrutide’s triple receptor mechanism distinguishes it from both semaglutide (GLP-1 mono-agonist) and tirzepatide (GLP-1/GIP dual agonist). The addition of glucagon receptor agonism is hypothesised to drive greater energy expenditure, making it a distinct research tool for studying incretin receptor pharmacology and comparative agonist biology.